BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gossard AA, Talwalkar JA. Cholestatic liver disease. Med Clin North Am 2014;98:73-85. [PMID: 24266915 DOI: 10.1016/j.mcna.2013.09.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Vilas-Boas V, Cooreman A, Gijbels E, Van Campenhout R, Gustafson E, Ballet S, Annaert P, Cogliati B, Vinken M. Primary hepatocytes and their cultures for the testing of drug-induced liver injury. Adv Pharmacol 2019;85:1-30. [PMID: 31307583 DOI: 10.1016/bs.apha.2018.08.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
2 Li S, Ni A, Feng GS. Bridging cell surface receptor with nuclear receptors in control of bile acid homeostasis. Acta Pharmacol Sin 2015;36:113-8. [PMID: 25500873 DOI: 10.1038/aps.2014.118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
3 Gitto S, Guarneri V, Sartini A, Andreone P. The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives. Expert Rev Gastroenterol Hepatol 2018;12:165-71. [PMID: 29082798 DOI: 10.1080/17474124.2018.1399060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Jiang B, Yuan G, Wu J, Wu Q, Li L, Jiang P. Prevotella copri ameliorates cholestasis and liver fibrosis in primary sclerosing cholangitis by enhancing the FXR signalling pathway. Biochim Biophys Acta Mol Basis Dis 2021;1868:166320. [PMID: 34896545 DOI: 10.1016/j.bbadis.2021.166320] [Reference Citation Analysis]
5 Ommati MM, Mohammadi H, Mousavi K, Azarpira N, Farshad O, Dehghani R, Najibi A, Kamran S, Niknahad H, Heidari R. Metformin alleviates cholestasis-associated nephropathy through regulating oxidative stress and mitochondrial function. Liver Research 2021;5:171-80. [DOI: 10.1016/j.livres.2020.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
6 Zhou R, Fan X, Schnabl B. Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. Transl Res 2019;209:22-38. [PMID: 30853445 DOI: 10.1016/j.trsl.2019.02.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
7 Ommati MM, Farshad O, Mousavi K, Taghavi R, Farajvajari S, Azarpira N, Moezi L, Heidari R. Agmatine alleviates hepatic and renal injury in a rat model of obstructive jaundice. PharmaNutrition 2020;13:100212. [DOI: 10.1016/j.phanu.2020.100212] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
8 Zhang J, Guo X, Hamada T, Yokoyama S, Nakamura Y, Zheng J, Kurose N, Ishigaki Y, Uramoto H, Tanimoto A, Yamada S. Protective Effects of Peroxiredoxin 4 (PRDX4) on Cholestatic Liver Injury. Int J Mol Sci 2018;19:E2509. [PMID: 30149550 DOI: 10.3390/ijms19092509] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
9 Ommati MM, Farshad O, Azarpira N, Ghazanfari E, Niknahad H, Heidari R. Silymarin mitigates bile duct obstruction-induced cholemic nephropathy. Naunyn Schmiedebergs Arch Pharmacol 2021;394:1301-14. [PMID: 33538845 DOI: 10.1007/s00210-020-02040-8] [Reference Citation Analysis]
10 Yang JY, Li M, Zhang CL, Liu D. Pharmacological properties of baicalin on liver diseases: a narrative review. Pharmacol Rep 2021;73:1230-9. [PMID: 33595821 DOI: 10.1007/s43440-021-00227-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Vongbhavit K, Underwood MA. Predictive Value of the Aspartate Aminotransferase to Platelet Ratio Index for Parenteral Nutrition-Associated Cholestasis in Premature Infants With Intestinal Perforation. JPEN J Parenter Enteral Nutr 2018;42:797-804. [PMID: 28792861 DOI: 10.1177/0148607117722755] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
12 Iversen K, Drivdal LM, Billaud Feragen KJ, Geirdal AØ. Quality of life in adults with lymphedema cholestasis syndrome 1. Health Qual Life Outcomes 2018;16:146. [PMID: 30045736 DOI: 10.1186/s12955-018-0972-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
13 Mariotti V, Strazzabosco M, Fabris L, Calvisi DF. Animal models of biliary injury and altered bile acid metabolism. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1254-1261. [PMID: 28709963 DOI: 10.1016/j.bbadis.2017.06.027] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 10.2] [Reference Citation Analysis]
14 Onalan AK, Tuncal S, Kilicoglu S, Celepli S, Durak E, Kilicoglu B, Devrim E, Barlas AM, Kismet K. Effect of sılymarın on oxıdatıve stress and lıver hıstopathology ın experımental obstructıve jaundıce model. Acta Cir Bras 2016;31:801-6. [PMID: 28076503 DOI: 10.1590/S0102-865020160120000004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
15 Koop AH, Mousa OY, Pham LE, Corral-Hurtado JE, Pungpapong S, Keaveny AP. An Argument for Vitamin D, A, and Zinc Monitoring in Cirrhosis. Ann Hepatol 2018;17:920-32. [PMID: 30600288 DOI: 10.5604/01.3001.0012.7192] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
16 Heidari R, Mandegani L, Ghanbarinejad V, Siavashpour A, Ommati MM, Azarpira N, Najibi A, Niknahad H. Mitochondrial dysfunction as a mechanism involved in the pathogenesis of cirrhosis-associated cholemic nephropathy. Biomedicine & Pharmacotherapy 2019;109:271-80. [DOI: 10.1016/j.biopha.2018.10.104] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
17 Abdel-rahman N, Sharawy MH, Megahed N, El-awady MS. Vitamin D3 abates BDL-induced cholestasis and fibrosis in rats via regulating Hedgehog pathway. Toxicology and Applied Pharmacology 2019;380:114697. [DOI: 10.1016/j.taap.2019.114697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Cardoso R, Casela A, Lopes S, Agostinho C, Souto P, Camacho E, Almeida N, Mendes S, Gomes D, Sofia C. Portal Hypertensive Biliopathy: An Infrequent Cause of Biliary Obstruction. GE Port J Gastroenterol 2015;22:65-9. [PMID: 28868376 DOI: 10.1016/j.jpge.2015.01.003] [Reference Citation Analysis]
19 Keihanian T, Barakat MT, Tejaswi S, Mishra R, Carlson CJ, Brandabur JJ, Girotra M. Role of Endoscopic Retrograde Cholangiopancreatography in the Diagnosis and Management of Cholestatic Liver Diseases. Clin Liver Dis 2022;26:51-67. [PMID: 34802663 DOI: 10.1016/j.cld.2021.08.006] [Reference Citation Analysis]
20 Vinken M. In vitro prediction of drug-induced cholestatic liver injury: a challenge for the toxicologist. Arch Toxicol 2018;92:1909-12. [PMID: 29574564 DOI: 10.1007/s00204-018-2201-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
21 Sato K, Hall C, Glaser S, Francis H, Meng F, Alpini G. Pathogenesis of Kupffer Cells in Cholestatic Liver Injury. Am J Pathol. 2016;186:2238-2247. [PMID: 27452297 DOI: 10.1016/j.ajpath.2016.06.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]
22 Pate J, Gutierrez JA, Frenette CT, Goel A, Kumar S, Manch RA, Mena EA, Pockros PJ, Satapathy SK, Yimam KK, Gish RG. Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel. BMJ Open Gastroenterol 2019;6:e000256. [PMID: 30815273 DOI: 10.1136/bmjgast-2018-000256] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
23 Gondal B, Aronsohn A. A Systematic Approach to Patients with Jaundice. Semin Intervent Radiol 2016;33:253-8. [PMID: 27904243 DOI: 10.1055/s-0036-1592331] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
24 Ommati MM, Attari H, Siavashpour A, Shafaghat M, Azarpira N, Ghaffari H, Moezi L, Heidari R. Mitigation of cholestasis-associated hepatic and renal injury by edaravone treatment: Evaluation of its effects on oxidative stress and mitochondrial function. Liver Research 2021;5:181-93. [DOI: 10.1016/j.livres.2020.10.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]